
浏览全部资源
扫码关注微信
1.山东中医药大学 附属医院,济南 250014
2.山东中医药大学 中医学院,济南 250014
3.山东省中医药研究院,济南 250014
4.齐鲁工业大学(山东省科学院)山东省分析测试中心,济南 250014
罗雅琴,硕士,主治医师,硕士生导师,从事中西医结合治疗血液病的临床与实验研究,E-mail:luoluo1460@yeah.net
黄伟,博士,副研究员,硕士生导师,从事中药药效物质基础及作用机理研究,E-mail:huangwei986@126.com
收稿日期:2022-04-12,
网络出版日期:2022-06-16,
纸质出版日期:2022-09-05
移动端阅览
罗雅琴,于新阳,张月明等.基于AMPK/mTOR/ULK1信号通路介导的自噬探讨芪黄益气摄血方治疗免疫性血小板减少症模型小鼠的作用机制[J].中国实验方剂学杂志,2022,28(17):43-51.
LUO Yaqin,YU Xinyang,ZHANG Yueming,et al.Mechanism of Qihuang Yiqi Shexue Prescription in Treatment of ITP Model Mice Based on Autophagy Mediated by AMPK/mTOR/ULK1 Signaling Pathway[J].Chinese Journal of Experimental Traditional Medical Formulae,2022,28(17):43-51.
罗雅琴,于新阳,张月明等.基于AMPK/mTOR/ULK1信号通路介导的自噬探讨芪黄益气摄血方治疗免疫性血小板减少症模型小鼠的作用机制[J].中国实验方剂学杂志,2022,28(17):43-51. DOI: 10.13422/j.cnki.syfjx.20221636.
LUO Yaqin,YU Xinyang,ZHANG Yueming,et al.Mechanism of Qihuang Yiqi Shexue Prescription in Treatment of ITP Model Mice Based on Autophagy Mediated by AMPK/mTOR/ULK1 Signaling Pathway[J].Chinese Journal of Experimental Traditional Medical Formulae,2022,28(17):43-51. DOI: 10.13422/j.cnki.syfjx.20221636.
目的
2
基于腺苷酸活化蛋白激酶/哺乳动物雷帕霉素靶蛋白/Unc-51样激酶1(AMPK/mTOR/ULK1)信号通路介导的自噬探讨芪黄益气摄血方治疗免疫性血小板减少症(ITP)模型小鼠的作用机制。
方法
2
50只BALB/c小鼠随机分为5组,分别为正常组、模型组、芪黄益气摄血方高、低剂量组和强的松组,每组10只。采用豚鼠抗小鼠血小板血清(APS)腹腔注射方法,建立ITP小鼠模型;注射APS后的第8天,各组分别灌胃给药,连续14 d。检测外周血血小板计数(PLT)和血红蛋白(Hb)浓度变化;分离脾脏、胸腺组织,称质量,计算脏器指数;取胸骨做骨髓涂片,显微镜下进行骨髓巨核细胞分类;酶联免疫吸附测定法(ELISA)检测血清血小板生成素(TPO)、白细胞介素-6(IL-6)、白细胞介素-10(IL-10)、肿瘤坏死因子-
α
(TNF-
α
)、转化生长因子-
β
1
(TGF-
β
1
)、
γ
干扰素(IFN-
γ
)水平;实时荧光定量聚合酶链式反应(Real-time PCR)检测脾脏AMPK、mTOR、ULK1、微管相关蛋白1轻链3(LC3)、自噬关键分子酵母Atg6同系物(Beclin1)、p62 mRNA表达水平;蛋白免疫印迹法(Western blot)检测脾脏AMPK、p-AMPK、p-mTOR、p-ULK1、LC3Ⅱ/LC3Ⅰ、Beclin1、p62蛋白表达水平。
结果
2
与正常组比较,模型组小鼠外周血PLT计数、Hb及TPO水平明显下降(
P<
0.05,
P<
0.01),脾脏和胸腺指数显著升高(
P
<
0.01),骨髓产板巨核细胞数显著减少(
P
<
0.01),血清IL-6、TNF-
α
、IFN-
γ
水平显著升高(
P<
0.01),而IL-10、TGF-
β
1
水平显著降低(
P<
0.01);与模型组比较,芪黄益气摄血方高、低剂量组及强的松组显著增加模型小鼠PLT计数、TPO水平(
P<
0.01),明显降低脾脏和胸腺指数(
P<
0.05,
P<
0.01),明显增加骨髓产板巨核细胞数(
P<
0.05,
P<
0.01),明显降低血清IL-6、TNF-
α
、IFN-
γ
水平(
P
<
0.05,
P<
0.01),明显提高IL-10、TGF-
β
1
水平(
P
<
0.05,
P<
0.01);与芪黄益气摄血方低剂量组比较,芪黄益气摄血方高剂量组和强的松组在改善PLT计数、细胞炎性因子水平方面呈现不同程度的显著性差异(
P
<
0.05,
P
<
0.01)。Real-time PCR和Western blot结果显示,与正常组比较,模型组小鼠脾脏AMPK、LC3、Beclin1 mRNA和p-AMPK/AMPK、LC3Ⅱ/LC3Ⅰ、Beclin1蛋白表达均明显上调(
P<
0.05,
P<
0.01),mTOR、ULK1、p62 mRNA和p-mTOR、p-ULK1、p62蛋白表达水平明显下调(
P<
0.05,
P<
0.01);与模型组比较,芪黄益气摄血方高、低剂量组及强的松组可明显下调脾脏AMPK、LC3、Beclin1 mRNA和p-AMPK/AMPK、LC3Ⅱ/LC3Ⅰ、Beclin1蛋白表达(
P<
0.05,
P<
0.01),同时明显上调mTOR、ULK1、p62 mRNA和p-mTOR、p-ULK1、p62蛋白表达水平(
P<
0.05,
P<
0.01)。
结论
2
芪黄益气摄血方可能通过调控AMPK/mTOR/ULK1信号通路抑制自噬的过度发生,从而调节免疫失耐受,发挥治疗ITP作用。
Objective
2
To explore the mechanism of Qihuang Yiqi Shexue prescription (QHYQSX) in the treatment of immune thrombocytopenia (ITP) model mice based on the autophagy mediated by the adenosine monophosphate-activated protein kinase (AMPK)/mammalian target of rapamycin (mTOR)/Unc-51-like kinase 1 (ULK1) signaling pathway.
Method
2
Fifty BALB/c mice were randomly divided into normal group, model group, high- and low-dose QHYQSX groups, and prednisone group, with 10 mice in each group. The ITP model was induced by intraperitoneal injection of anti-platelet serum (APS) of guinea pig. On the 8th day of the APS injection, drugs were administered by gavage for 14 days. Peripheral blood platelet (PLT) count and hemoglobin (Hb) concentration were detected. Spleen and thymus were separated, weighed, and the organ index was calculated. Sternum was sampled for bone marrow smear, and bone marrow megakaryocytes were classified under a microscope. Thrombopoietin (TPO), interleukin-6 (IL-6), IL-10, tumor necrosis factor-
α
(TNF-
α
), transforming growth factor-
β
1
(TGF-
β
1
), and interferon-
γ
(IFN-
γ
) in the serum were detected by enzyme-linked immunosorbent assay(ELISA). AMPK, mTOR, ULK1, microtubule-associated protein light chain 3 (LC3), Beclin1, and p62 mRNA expression levels in the spleen were detected by Real-time fluorescence-based quantitative polymerase chain reaction (Real-time PCR). The protein expression of AMPK, p-AMPK, p-mTOR, p-ULK1, LC3Ⅱ/LC3Ⅰ, Beclin1, and p62 in the spleen was detected by Western blot.
Result
2
Compared with the normal group, the model group showed reduced peripheral blood PLT count, Hb, and TPO levels (
P
<
0.05,
P
<
0.01), increased spleen and thymus indexes (
P
<
0.01), decreased number of bone marrow megakaryocytes (
P
<
0.01), elevated serum levels of IL-6, TNF-
α
, and IFN-
γ
(
P
<
0.01), and reduced IL-10 and TGF-
β
1
levels (
P
<
0.01). Compared with the model group, the groups with drug intervention showed increased PLT counts and TPO levels (
P
<
0.01), decreased spleen and thymus indexes (
P
<
0.05,
P
<
0.01), elevated number of bone marrow megakaryocytes (
P
<
0.05,
P
<
0.01), reduced serum levels of IL-6, TNF-
α
, and IFN-
γ
(
P
<
0.05,
P
<
0.01), and up-regulated IL-10 and TGF-
β
1
levels (
P
<
0.05,
P
<
0.01). Compared with the low-dose QHYQSX group, the high-dose QHYQSX group and the prednisone group showed different degrees of significant differences in improving PLT counts and levels of cellular inflammatory factors (
P
<
0.05,
P
<
0.01). Real-time PCR and Western blot results showed that compared with the normal group, the model group showed up-regulated mRNA expression of AMPK, LC3, and Beclin1 and protein expression of p-AMPK/AMPK, LC3Ⅱ/LC3Ⅰ, and Beclin1 in the spleen (
P
<
0.05,
P
<
0.01), and down-regulated mRNA expression of mTOR, ULK1, and p62 and protein expression of p-mTOR, p-ULK1, and p62 (
P
<
0.05,
P
<
0.01). Compared with the results in the model group, high- and low-dose QHYQSX and prednisone could down-regulate the mRNA expression of AMPK, LC3, and Beclin1 and protein expression of p-AMPK/AMPK, LC3Ⅱ/LC3Ⅰ, and Beclin1 in the spleen (
P
<
0.05,
P
<
0.01), and up-regulate the mRNA expression of mTOR, ULK1, and p62 and protein expression of p-mTOR, p-ULK1, and p62 (
P
<
0.05,
P
<
0.01).
Conclusion
2
QHYQSX may inhibit excessive autophagy by regulating the AMPK/mTOR/ULK1 signaling pathway, thereby regulating immune intolerance and playing a role in the treatment of ITP.
SNYDER C F , MATHIAS S D , CELLA D , et al . Health-related quality of life of immune thrombocytopenic purpura patients:Results from a web-based survey [J]. Curr Med Res Opin , 2008 , 24 ( 10 ): 2767 - 2776 .
MCMILLAN R , BUSSEL J B , GEORGE J N , et al . Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura [J]. Am J Hematol , 2010 , 83 ( 2 ): 150 - 154 .
侯明 . 免疫性血小板减少症的治疗进展 [J]. 临床血液学杂志 , 2020 , 33 ( 1 ): 6 - 9 .
张玲 , 陈科 , 张雅月 , 等 . 健脾益气摄血方治疗免疫性血小板减少症临床疗效及其机制研究 [J]. 北京中医药大学学报 , 2020 , 43 ( 4 ): 343 - 352 .
WALSH C M , EDINGER A L . The complex interplay between autophagy,apoptosis,and necrotic signals promotes T-cell homeostasis [J]. Immunol Rev , 2010 , 236 ( 1 ): 95 - 109 .
SHAN N N , DONG L L , ZHANG X M , et al . Targeting autophagy as a potential therapeutic approach for immune thrombocytopenia therapy [J]. Crit Rev Oncol Hematol , 2016 , 100 : 11 - 15 .
罗雅琴 , 黄伟 . 芪黄益气摄血方对ITP模型小鼠Th1/Th2细胞因子及转录因子T-bet/GATA3表达的影响 [J]. 时珍国医国药 , 2022 , 33 ( 1 ): 48 - 51 .
罗雅琴 , 黄伟 . 芪黄益气摄血方对免疫性血小板减少症模型小鼠Th17/Treg细胞因子及转录因子ROR- γ t/Foxp3表达的影响 [J]. 中药药理与临床 , 2021 , 37 ( 6 ): 129 - 133 .
罗雅琴 , 黄伟 . 芪黄益气摄血方对免疫性血小板减少症模型小鼠的治疗作用及抗炎机制研究 [J]. 中国药物警戒 , 2022 , doi: 11.5219.R.20220207.1822.008.html http://dx.doi.org/11.5219.R.20220207.1822.008.html .
富琦 , 范颖 , 王家辉 , 等 . 免疫性血小板减少性紫癜病证结合动物模型建立与评价 [J]. 中国中医基础医学杂志 , 2004 , 10 ( 2 ): 30 - 32 .
朱长乐 , 何昊 , 徐玥 , 等 . 健脾摄血方对ITP模型小鼠生命体征和脏器指数的影响 [J]. 中医药学报 , 2017 , 45 ( 2 ): 10 - 14 .
郎海燕 , 褚雨霆 , 马薇 , 等 . 免疫性血小板减少症病证结合动物模型研究 [J]. 中医药信息 , 2017 , 34 ( 1 ): 39 - 43 .
祁烁 , 李天天 , 何昊 , 等 . 强的松对ITP模型小鼠血管活性物质调节作用研究 [J]. 现代生物医学进展 , 2017 , 17 ( 34 ): 6601 - 6606 .
徐颖超 , 宋玲玲 , 刘朝霞 . 原发免疫性血小板减少症的中西医研究进展 [J]. 世界最新医学信息文摘 , 2019 , 19 ( 8 ): 128 - 129 .
崔清彦 , 颉迎新 , 王文欣 , 等 . 免疫性血小板减少症发病机制的研究进展 [J]. 山东医药 , 2020 , 60 ( 4 ): 102 - 105 .
AUDIA S , MAHÉVAS M , SAMSON M , et al . Pathogenesis of immune thrombocytopenia [J]. Autoimmun Rev , 2017 , 16 ( 6 ): 620 - 632 ..
WEI Y , HOU M . T cells in the pathogenesis of immune thrombocytopenia [J]. Semin Hematol , 2016 , 53 ( Suppl 1 ): S13 - S15 .
李姜惠子 , 刘洋 , 王秀娟 , 等 . sPD-1/sPD-L1与Th1/Th2及Th17/Treg相关细胞因子在原发免疫性血小板减少症中的研究 [J]. 中国免疫学杂志 , 2019 , 35 ( 4 ): 467 - 470 .
王明镜 , 许勇钢 , 丁晓庆 , 等 . 免疫性血小板减少症患者Th1/Th2细胞失衡与特异性转录因子表达异常 [J]. 临床血液学杂志 , 2018 , 31 ( 3 ): 379 - 382 .
谢东杰 , 王爱迪 , 刘宝山 . CD4~+T细胞在原发性免疫性血小板减少症中作用机制的研究进展 [J]. 中国免疫学杂志 , 2017 , 33 ( 9 ): 1415 - 1417 .
王明镜 , 许勇钢 , 丁晓庆 , 等 . 免疫性血小板减少症患者促炎因子与抑炎因子分泌失衡 [J]. 中国实验血液学杂志 , 2018 , 26 ( 2 ): 522 - 527 .
王敏 , 余薇 , 查文良 . 自噬和线粒体自噬在糖尿病心肌病中的作用研究进展 [J]. 中国药理学通报 , 2018 , 34 ( 10 ): 1337 - 1340 .
YANG H P , LI L , ZHOU K C , et al . Shengmai injection attenuates the cerebral ischemia/reperfusion induced autophagy via modulation of the AMPK,mTOR and JNK pathways [J]. Pharm Biol , 2016 , 54 ( 10 ): 2288 - 2297 .
XUE T F , DING X , JI J , et al . PD149163 induces hypothermia to protect against brain injury in acute cerebral ischemic rats [J]. J Pharmacol Sci , 2017 , 135 ( 3 ): 105 - 113 .
WATAYA-KANEDA M . Mammalian target of rapamycin and tuberous sclerosis complex [J]. J Dermatol Sci , 2015 , 79 ( 2 ): 93 - 100 .
GWINN D M , SHACKELFORD D B , EGAN D F , et al . AMPK phosphorylation of raptor mediates a metabolic checkpoint [J]. Mol Cell , 2008 , 30 ( 2 ): 214 - 226 .
CHUN Y , KIM J . AMPK-mTOR signaling and cellular adaptations in hypoxia [J]. Int J Mol Sci , 2021 , 22 ( 18 ): 9765 - 9787 .
KIM J , KUNDU M , VIOLLET B , et al . AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1 [J]. Nat Cell Biol , 2011 , 13 ( 2 ): 132 - 141 .
TIAN W L , LI W , CHEN Y Q , et al . Phosphorylation of ULK1 by AMPK regulates translocation of ULK1 to mitochondria and mitophagy [J]. FEBS Lett , 2015 , 589 ( 15 ): 1847 - 1854 .
0
浏览量
19
下载量
5
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621